Grufity logoGrufity logo

Bristol-Myers Squibb Co Stock Research

BMY

66.97USD-0.27(-0.40%)Delayedas of 23 Mar 2023, 01:26 pm

Market Summary

USD66.97-0.27
Delayedas of 23 Mar 2023, 01:26 pm
-0.40%

BMY Stock Price

BMY RSI Chart

BMY Valuation

Market Cap

142.4B

Price/Earnings (Trailing)

22.5

Price/Sales (Trailing)

3.08

EV/EBITDA

6.87

Price/Free Cashflow

11.92

BMY Price/Sales (Trailing)

BMY Profitability

EBT Margin

16.71%

Return on Equity

20.37%

Return on Assets

6.53%

Free Cashflow Yield

8.39%

BMY Fundamentals

BMY Revenue

Revenue (TTM)

46.2B

Revenue Y/Y

-4.83%

Revenue Q/Q

1.68%

BMY Earnings

Earnings (TTM)

6.3B

Earnings Y/Y

-14.76%

Earnings Q/Q

25.9%

Price Action

52 Week Range

65.2881.44
(Low)(High)

Last 7 days

0.3%

Last 30 days

-7.8%

Last 90 days

-10.0%

Trailing 12 Months

-1.1%

BMY Financial Health

Current Ratio

1.25

Debt/Equity

1.19

Debt/Cashflow

0.36

BMY Investor Care

Dividend Yield

2.81%

Dividend/Share (TTM)

2.16

Buy Backs (1Y)

4.21%

Diluted EPS (TTM)

2.95

Peers (Alternatives to Bristol-Myers Squibb)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
396.9B
94.9B
-5.16% -10.64%
22.12
4.18
1.25% -14.07%
298.8B
28.5B
-5.67% 20.74%
47.85
10.47
0.79% 11.88%
272.8B
59.3B
-1.75% 40.02%
17.88
4.63
21.72% 11.27%
226.2B
100.3B
-8.43% -20.95%
7.21
2.25
23.43% 42.74%
142.4B
46.2B
-7.78% -1.12%
22.5
3.08
-0.49% -9.54%
MID-CAP
4.5B
4.5B
-0.20% -5.41%
-32.05
1.01
7.56% -104.06%
3.3B
2.2M
105.10% 171.03%
-10.52
1.5K
-80.71% -4.88%
SMALL-CAP
1.9B
667.2M
-9.96% 17.66%
31.57
2.87
15.09% 13.64%
1.6B
602.5M
-17.77% -52.80%
-2.78
2.67
18.18% -18.59%
923.6M
478.9M
-11.35% -65.42%
-0.29
1.93
-31.50% -634.70%
792.9M
285.2M
-7.22% -37.95%
3.6
2.78
-27.21% -40.28%
726.9M
114.5M
-15.28% -37.42%
-4.31
6.35
27.90% 57.40%
539.5M
29.8M
-40.95% -47.43%
-6.21
18.13
340.05% 4.35%
400.7M
51.5M
-2.49% -0.39%
-5.64
7.78
18.32% -984.05%
94.1M
2.3B
-43.99% -88.43%
-0.03
0.04
-22.53% -376.66%

Financials for Bristol-Myers Squibb

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue-1.2%46,15946,73847,14446,96046,385
  S&GA Expenses-1.1%7,8147,9027,7607,8557,690
  R&D Expenses-0.1%9,5099,51710,07910,23610,195
Costs and Expenses-1.5%38,44639,02639,48439,70538,287
EBITDA-0.3%19,38919,44619,54619,355-
EBITDA Margin1.0%0.42*0.42*0.42*0.41*-
Earnings Before Taxes0.0%7,7137,7127,6607,2558,098
EBT Margin1.3%0.17*0.17*0.16*0.15*-
Interest Expenses-0.9%1,4001,4131,4421,500-
Net Income-5.2%6,3276,6776,6176,2516,994
Net Income Margin-4.1%0.14*0.14*0.14*0.13*-
Free Cahsflow-6.1%11,94812,72514,28115,142-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets-1.4%96,82098,196100,357103,034109,314
  Current Assets1.8%27,27326,79630,18630,12133,262
    Cash Equivalents18.0%9,1237,73410,75012,36913,979
  Inventory12.8%2,3392,0742,1422,1042,095
  Net PPE3.6%6,2556,0355,9706,0476,049
  Goodwill0.2%21,14921,11220,44620,50020,502
Liabilities0.4%65,70265,46267,69671,38973,308
  Current Liabilities15.6%21,89018,93020,91522,82121,868
    LT Debt, Current-59.0%1,9034,6467,2974,764-
    LT Debt, Non Current-5.2%35,05636,96637,10737,45039,605
Shareholder's Equity-4.9%31,06132,67132,60031,58035,946
  Retained Earnings3.4%25,50324,67524,21723,94823,820
  Additional Paid-In Capital0.5%45,16544,95644,37543,75644,361
Shares Outstanding-0.4%2,1262,1352,129--
Minority Interest-9.5%57.0063.0061.0065.0060.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-5.4%13,06613,81715,39616,19516,207
  Share Based Compensation-3.0%457471498539583
Cashflow From Investing43.3%-1,062-1,874-769-300-538
Cashflow From Financing4.1%-16,962-17,683-14,920-14,582-16,224
  Dividend Payments1.0%4,6344,5884,5244,4734,396
  Buy Backs-5.3%8,0018,4528,2769,5126,287

Risks for BMY

What is the probability of a big loss on BMY?

48.1%


Probability that Bristol-Myers Squibb stock will be more than 20% underwater in next one year

1.9%


Probability that Bristol-Myers Squibb stock will be more than 30% underwater in next one year.

0%


Probability that Bristol-Myers Squibb stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BMY drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Bristol-Myers Squibb was unfortunately bought at previous high price.

Drawdowns

Returns for BMY

Cumulative Returns on BMY

8.6%


10-Year Cumulative Returns

4.0%


7-Year Cumulative Returns

3.2%


5-Year Cumulative Returns

10.1%


3-Year Cumulative Returns

What are the long-term rolling returns for BMY?

FIve years rolling returns for Bristol-Myers Squibb.

Annualized Returns

Which funds bought or sold BMY recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-15
B. Riley Wealth Advisors, Inc.
added
5.8
1,002,450
15,186,500
0.42%
2023-03-13
Claro Advisors LLC
added
20.27
145,154
1,313,150
0.43%
2023-03-10
MATHER GROUP, LLC.
added
61.00
277,270
717,270
0.01%
2023-03-10
BAILLIE GIFFORD & CO
unchanged
-
-47.00
32,953
-%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-1.68
-802,303
160,959,000
0.18%
2023-03-08
SHEETS SMITH WEALTH MANAGEMENT
added
0.42
71,000
4,437,000
0.69%
2023-03-08
Capital Asset Advisory Services LLC
added
16.1
293,781
1,843,780
0.15%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-3.37
-1,172,000
52,076,000
0.26%
2023-03-06
BIRMINGHAM CAPITAL MANAGEMENT CO INC/AL
unchanged
-
38,515
3,195,520
1.21%
2023-03-06
NORTH STAR ASSET MANAGEMENT INC
reduced
-8.03
-56,783
769,217
0.05%

1–10 of 45

Latest Funds Activity

Are funds buying BMY calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own BMY
No. of Funds

Bristol-Myers Squibb News

StockNews.com

JNJ: The Strongest Pharma Stock This Week.

StockNews.com,
51 minutes ago

DirectorsTalk Interviews

The Motley Fool

StockNews.com

Schedule 13G FIlings of Bristol-Myers Squibb

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
9.54%
202,927,620
SC 13G/A
Feb 07, 2023
blackrock inc.
8.1%
172,720,377
SC 13G/A
Feb 09, 2022
vanguard group inc
9.00%
199,834,483
SC 13G/A
Feb 01, 2022
blackrock inc.
7.6%
169,226,706
SC 13G/A
Feb 10, 2021
vanguard group inc
8.82%
199,340,458
SC 13G/A
Jan 29, 2021
blackrock inc.
7.6%
172,464,804
SC 13G/A
Feb 12, 2020
vanguard group inc
8.32%
194,860,154
SC 13G/A
Feb 05, 2020
blackrock inc.
7.3%
171,343,446
SC 13G/A
Jan 28, 2020
wellington management group llp
3.57%
83,470,877
SC 13G/A

BMY Fair Value

Bristol-Myers Squibb fair value in different scenarios

The table shows the Fair Value estimates for Bristol-Myers Squibb for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

-

-

-

-

-

-

-

-

-

-
Current Inflation

33.86

-49.44%

40.90

-38.93%

62.78

-6.26%

117.02

74.73%

143.97

114.98%
Very High Inflation

-

-

-

-

-

-

-

-

-

-

Historical Bristol-Myers Squibb Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Bristol-Myers Squibb

View All Filings
Date Filed Form Type Document
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading

Latest Insider Trading transactions for BMY

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-10
Mily Elizabeth
acquired
-
-
3,458
evp, strategy & bd
2023-03-10
Powell Ann
sold (taxes)
-1,104,590
65.71
-16,810
evp, chief human resources
2023-03-10
Hirawat Samit
acquired
-
-
38,978
evp,chief med.offr.,drug dev.
2023-03-10
BOERNER CHRISTOPHER S.
acquired
-
-
8,568
evp, chief commercial officer
2023-03-10
LEUNG SANDRA
acquired
-
-
8,731
evp, general counsel
2023-03-10
Mily Elizabeth
sold (taxes)
-922,568
65.71
-14,040
evp, strategy & bd
2023-03-10
Hirawat Samit
sold (taxes)
-1,471,580
65.71
-22,395
evp,chief med.offr.,drug dev.
2023-03-10
Mily Elizabeth
acquired
-
-
29,636
evp, strategy & bd
2023-03-10
Elkins David V
acquired
-
-
71,871
evp, chief financial officer
2023-03-10
Caforio Giovanni
acquired
-
-
234,676
board chair and ceo

1–10 of 50

Giovanni Caforio
32200
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

BMY Income Statement

2022-12-31
CONSOLIDATED STATEMENTS OF EARNINGS - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Total Revenues$ 46,159$ 46,385$ 42,518
Cost of products sold[1]10,1379,94011,773
Marketing, selling and administrative7,8147,6907,661
Research and development9,50910,19510,048
Acquired IPRD8151,15912,533
Amortization of acquired intangible assets9,59510,0239,688
Other (income)/expense, net576(720)(2,314)
Total Expenses38,44638,28749,389
Earnings/(Loss) Before Income Taxes7,7138,098(6,871)
Provision for Income Taxes1,3681,0842,124
Net Earnings/(Loss)6,3457,014(8,995)
Noncontrolling Interest182020
Net Earnings(Loss) Attributable to BMS$ 6,327$ 6,994$ (9,015)
Earnings per common share attributable to BMS, basic (in usd per share)$ 2.97$ 3.15$ (3.99)
Earnings per common share attributable to BMS, diluted (in usd per share)$ 2.95$ 3.12$ (3.99)
Net product sales   
Total Revenues$ 44,671$ 45,055$ 41,321
Alliance and other revenues   
Total Revenues$ 1,488$ 1,330$ 1,197
[1]Excludes amortization of acquired intangible assets.

BMY Balance Sheet

2022-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Current Assets:  
Cash and cash equivalents$ 9,123$ 13,979
Marketable debt securities1302,987
Receivables9,8869,369
Inventories2,3392,095
Other current assets5,7954,832
Total Current Assets27,27333,262
Property, plant and equipment6,2556,049
Goodwill21,14920,502
Other intangible assets35,85942,527
Deferred income taxes1,3441,439
Other non-current assets4,9405,535
Total Assets96,820109,314
Current Liabilities:  
Short-term debt obligations4,2644,948
Accounts payable3,0402,949
Other current liabilities14,58613,971
Total Current Liabilities21,89021,868
Deferred income taxes2,1664,501
Long-term debt35,05639,605
Other non-current liabilities6,5907,334
Total Liabilities65,70273,308
Commitments and contingencies
Bristol-Myers Squibb Company Shareholders’ Equity:  
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 2,991 in 2022 and 3,484 in 2021, liquidation value of $50 per share00
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.9 billion issued in 2022 and 2021292292
Capital in excess of par value of stock45,16544,361
Accumulated other comprehensive loss(1,281)(1,268)
Retained earnings25,50323,820
Less cost of treasury stock — 825 million common shares in 2022 and 747 million common shares in 2021(38,618)(31,259)
Total Bristol-Myers Squibb Company Shareholders’ Equity31,06135,946
Noncontrolling interest5760
Total Equity31,11836,006
Total Liabilities and Equity$ 96,820$ 109,314